SABCS2017

SABCS: Modest Weight Loss Cuts Postmenopause Breast Cancer Risk

SABCS: Modest Weight Loss Cuts Postmenopause Breast Cancer Risk

Postmenopausal women with weight gain had increased risk of triple-negative breast cancer, research indicates.

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

By

Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.

Most Influential in Breast Reconstruction Decision: Surgeon, Spouse, GP

Most Influential in Breast Reconstruction Decision: Surgeon, Spouse, GP

By

A study from French researchers identified which people are the most likely to influence a breast cancer patient's decision whether to undergo breast reconstruction. These findings were presented at SABCS 2017.

MOCHA App Helps Breast Cancer Survivors Achieve Weight-Loss Goals

MOCHA App Helps Breast Cancer Survivors Achieve Weight-Loss Goals

By

A team from Methodist Hospital Cancer Center discuss an app developed at the facility that helps breast cancer survivors with nutrition and physical activity at SABCS 2017.

Physical Examination Sufficient Work-up for Complaints of Breast Pain

Physical Examination Sufficient Work-up for Complaints of Breast Pain

By

A single-center analysis demonstrates likelihood that mastalgia indicates presence of breast cancer and extensiveness of common work-up for the complaint. These findings were presented at SABCS 2017.

Bioimpedance Spectroscopy Reduces Chronic BCRL in High-Risk Breast Cancer

Bioimpedance Spectroscopy Reduces Chronic BCRL in High-Risk Breast Cancer

By

Results of a study evaluating the effectiveness of bioimpedance spectroscopy in reducing incidence of chronic breast cancer-related lymphedema (BCRL) in high-risk patients with breast cancer were presented at SABCS 2017.

EMBRACE at Dana-Farber Improves Care in Metastatic Breast Cancer

EMBRACE at Dana-Farber Improves Care in Metastatic Breast Cancer

By

A team from Dana-Farber Cancer Institute describe EMBRACE, their comprehensive care program for patients with metastatic breast cancer at SABCS 2017.

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

By

Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.

Bio-individualized Diet Helps Breast Cancer Survivors Stabilize Weight, Glucose

Bio-individualized Diet Helps Breast Cancer Survivors Stabilize Weight, Glucose

By

Novel weight reduction plan helps breast cancer survivors achieve and maintain a healthy weight and glucose level, according to a presentation at SABCS 2017.

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

By

A review of 12 antiemetic regimens identified 3 that may be more effective than conventional regimens, a study presented at SABCS 2017 has shown.

Balancing Early Palliative Care With Active Treatment in Advanced Breast Cancer

Balancing Early Palliative Care With Active Treatment in Advanced Breast Cancer

By

An approach for incorporating palliative care into oncologic care early after diagnosis is explained in an education session at the 2017 SABCS.

Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis

Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis

By

A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.

Adjuvant Therapy Duration a Continuous Discussion in HR+ Breast Cancer

Adjuvant Therapy Duration a Continuous Discussion in HR+ Breast Cancer

By

Choosing the optimal adjuvant therapy option for a patient with early-stage HR-positive breast cancer should be a continuous discussion with the patient, according to a presentation at SABCS 2017.

Epigenetic Modulation, Checkpoint Inhibition Showed Potential in HER2 Breast Cancer

Epigenetic Modulation, Checkpoint Inhibition Showed Potential in HER2 Breast Cancer

By

Using a mouse model of HER2+ breast cancer, researchers tested the efficiency of combined epigenetic modulation and checkpoint inhibition using the histone deacetylase inhibitor ENT and antibodies for 2 checkpoint inhibitor proteins. These findings were presented at the 2017 SABCS.

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

By

A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

By

Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.

Oncotype DX Recurrence Score a Potential Marker of Hereditary Breast Cancer

Oncotype DX Recurrence Score a Potential Marker of Hereditary Breast Cancer

By

Researchers conducted a review of more than 400 patients with hormone receptor-positive breast cancer to determine if high Oncotype DX RS is associated with a greater likelihood the cancer is hereditary.

Markers Identified for Cardiotoxicity Due to Chemotherapy for Breast Cancer

Markers Identified for Cardiotoxicity Due to Chemotherapy for Breast Cancer

By

Biomarker analysis revealed markers for cardiotoxicity enabling early initiation of heart failure therapy in patients with breast cancer who were treated with chemotherapy.

Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions

Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions

By

Research presented at SABCS 2017 demonstrated the effect of refining the linear predictor for determining which patients with breast cancer would potentially benefit from adjuvant chemotherapy.

Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis

Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis

By

A retrospective analysis presented at 2017 SABCS reveals the factors that indicate a higher risk of developing brain metastases for women with HER2+ breast cancer.

Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer

Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer

By

Study findings presented at SABCS 2017 demonstrate that intermediate Oncotype DX scores are prognostic of overall survival for patients with early-stage breast cancer, particularly in younger women with the disease.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs